July 30, 2008

ThromboGenics announces private investors acquire 8% stake in the company... more »

June 30, 2008

ThromboGenics announces positive results from its Phase IIb trial of Microplasmin in Vitrectomy (MIVI III)... more »

June 18, 2008

ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody... more »

A conference call took place on June 18th ... replay »

June 3, 2008

ThromboGenics and BioInvent report positive Phase I results for anti-PlGF cancer therapeutic TB-403... more »

May 28, 2008

ThromboGenics announces the exercise of 172,629 warrants... more »

May 23, 2008

ThromboGenics presents further results of the Vitreomacular Traction Trial (MIVI IIT) at the Euretina Annual Meeting in Vienna... more »

May 13, 2008

ThromboGenics is today issuing a business update for the three month period ended 31 March 2008... more »

April 9, 2008

ThromboGenics announces that it has completed patient enrolment for its Phase II MITI IV study... more »

April 1, 2008

ThromboGenics announces that it has completed patient enrolment for its Phase IIb MIVI III trial... more »

March 31, 2008

ThromboGenics announces update of its financial calendar for 2008/2009... more »

March 18, 2008

ThromboGenics announces financial calendar for 2008/2009... more »

March13, 2008

ThromboGenics announces 2007 full year results... more »

January 18, 2008

ThromboGenics and BioInvent receive approval to begin clinical trials of TB-403 for the treatment of cancer... more »

history »